Evidence map›Paper›PMID 29496608›Full record

ArticleNeuroscience letters2018

Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice.

Yan Zhou, Rachel Crowley, Thomas Prisinzano, Mary Jeanne Kreek

Abstract read
In one paragraph

Article in Neuroscience letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. A Protecting-Group-Free Synthesis of (-)-Salvinorin A.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021
    Article
  6. Biased Opioid Ligands.Molecules (Basel, Switzerland) · 2020
    Review
  7. Article
  8. Terpenoids, Cannabimimetic Ligands, beyond theMolecules (Basel, Switzerland) · 2020
    Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yan ZhouLaboratory of the Biology of Addictive Diseases, The Rockefeller University, NY, USA. Electronic address: zhouya@rockefeller.edu.
Rachel CrowleyDepartment of Medicinal Chemistry, University of Kansas School of Pharmacy, Lawrence, KS, USA.
Thomas PrisinzanoDepartment of Medicinal Chemistry, University of Kansas School of Pharmacy, Lawrence, KS, USA.
Mary Jeanne KreekLaboratory of the Biology of Addictive Diseases, The Rockefeller University, NY, USA.
Rockefeller University · USUniversity of Kansas · US

Funding

Investigation of Neoclerodanes as Novel Opioid LigandsR01DA018151 · NIDA · UNIVERSITY OF KENTUCKY · PI PRISINZANO, THOMAS EDWARD · 2005 to 2020
$5.7M
TRAINING GRANT IN DYNAMIC ASPECTS OF CHEMICAL BIOLOGYT32GM008545 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LAMB, AUDREY L · 1994 to 2019
$4.9M
Role of hypothalamic-specific POMC deficiency in alcohol reward and drinkingR03AA021970 · NIAAA · ROCKEFELLER UNIVERSITY · PI ZHOU, YAN · 2015 to 2016
$170k
NIAAA NIH HHS R03 AA021970NIDA NIH HHS R01 DA018151NIGMS NIH HHS T32 GM008545
6 · The paper itself

Abstract

Alcohol relapse plays a major role in alcohol dependence and is an important focus for the treatment of alcoholism. The alcohol deprivation effect (ADE) is a widely used paradigm in rodents to model the relapse episodes that occur in human alcoholics. Mesyl Salvinorin B (MSB) is a potent and selective kappa opioid receptor (KOP-r) full agonist, with fewer side effects (e.g., sedation or anhedonia) than classic KOP-r full agonists and a longer duration of action in mice than the structurally similar salvinorin A. We have recently found that MSB prevents cocaine seeking in a rat self-administration model and reduces excessive alcohol drinking in a mouse escalation model via a KOP-r-mediated mechanism. Here, we further investigated whether MSB alone (0.3-3 mg/kg) or in combination with naltrexone (mu-opioid receptor antagonist at 1 mg/kg) altered alcohol "relapse" drinking using a mouse ADE paradigm. Both male and female mice, exposed to 3-week intermittent access alcohol drinking in a two-bottle choice paradigm with 24-h access every other day, developed excessive alcohol intake and then displayed pronounced ADE after 1-week abstinence. Acute administration of MSB prevented the ADE at 3 mg/kg in both male and female mice. Upon investigation of potential synergistic effects between naltrexone and MSB, we found that acute administration of a combination of MSB (0.3 mg/kg) and naltrexone (1 mg/kg) reduced the ADE at doses lower than those individual effective doses, with no sex difference. Our study suggests that the KOP-r full agonist MSB both alone and in combination with naltrexone shows potential in alcohol "relapse" treatment models.

Indexed as

Alcohol DrinkingAnimalsDiterpenesDiterpenes, ClerodaneEthanolFemaleMaleMesylatesMice, Inbred C57BLNaltrexoneNarcotic AntagonistsReceptors, Opioid, kappaRecurrenceDiterpenesDiterpenes, ClerodaneEthanolMesylatesmesyl salvinorin BNaltrexoneNarcotic AntagonistsReceptors, Opioid, kappaAlcohol deprivation effectCombined therapyKOP-rMesyl salvinorin BNaltrexoneRelapse

Identifiers

PMID29496608
PMCPMC6293468
OpenAlexW2790968355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.